136 related articles for article (PubMed ID: 28902347)
1. Measuring the response of human head and neck squamous cell carcinoma to irradiation in a microfluidic model allowing customized therapy.
Cheah R; Srivastava R; Stafford ND; Beavis AW; Green V; Greenman J
Int J Oncol; 2017 Oct; 51(4):1227-1238. PubMed ID: 28902347
[TBL] [Abstract][Full Text] [Related]
2. Analysis of radiation-induced cell death in head and neck squamous cell carcinoma and rat liver maintained in microfluidic devices.
Carr SD; Green VL; Stafford ND; Greenman J
Otolaryngol Head Neck Surg; 2014 Jan; 150(1):73-80. PubMed ID: 24098006
[TBL] [Abstract][Full Text] [Related]
3. A comparison of cell survival and heat shock protein expression after radiation in normal dermal fibroblasts, microvascular endothelial cells, and different head and neck squamous carcinoma cell lines.
Muschter D; Geyer F; Bauer R; Ettl T; Schreml S; Haubner F
Clin Oral Investig; 2018 Jul; 22(6):2251-2262. PubMed ID: 29307045
[TBL] [Abstract][Full Text] [Related]
4. Time-dose-response relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas.
Muriel VP; Tejada MR; de Dios Luna del Castillo J
Radiother Oncol; 2001 Aug; 60(2):137-45. PubMed ID: 11439208
[TBL] [Abstract][Full Text] [Related]
5. A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Hattersley SM; Sylvester DC; Dyer CE; Stafford ND; Haswell SJ; Greenman J
Ann Biomed Eng; 2012 Jun; 40(6):1277-88. PubMed ID: 21997391
[TBL] [Abstract][Full Text] [Related]
6. Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells.
Grünow J; Rong C; Hischmann J; Zaoui K; Flechtenmacher C; Weber KJ; Plinkert P; Hess J
J Exp Clin Cancer Res; 2017 Feb; 36(1):25. PubMed ID: 28166815
[TBL] [Abstract][Full Text] [Related]
7. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.
Todorovic V; Prevc A; Zakelj MN; Savarin M; Brozic A; Groselj B; Strojan P; Cemazar M; Sersa G
Radiat Oncol; 2019 Nov; 14(1):214. PubMed ID: 31775835
[TBL] [Abstract][Full Text] [Related]
9. Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation.
Reddy SP; Marks JE
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):797-802. PubMed ID: 9128954
[TBL] [Abstract][Full Text] [Related]
10. Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years.
Blatt S; Voelxen N; Sagheb K; Pabst AM; Walenta S; Schroeder T; Mueller-Klieser W; Ziebart T
Clin Oral Investig; 2016 Nov; 20(8):2097-2104. PubMed ID: 26728026
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck.
Stausbøl-Grøn B; Overgaard J
Radiother Oncol; 1999 Jan; 50(1):47-55. PubMed ID: 10225557
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
14. Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.
Spencer CR; Gay HA; Haughey BH; Nussenbaum B; Adkins DR; Wildes TM; DeWees TA; Lewis JS; Thorstad WL
Cancer; 2014 Dec; 120(24):3994-4002. PubMed ID: 25143048
[TBL] [Abstract][Full Text] [Related]
15. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
[TBL] [Abstract][Full Text] [Related]
16. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
17. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
[TBL] [Abstract][Full Text] [Related]
18. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Stadler P; Feldmann HJ; Creighton C; Kau R; Molls M
Radiother Oncol; 1998 Aug; 48(2):157-64. PubMed ID: 9783887
[TBL] [Abstract][Full Text] [Related]
19. Specific growth rates calculated from CTs in patients with head and neck squamous cell carcinoma: a retrospective study performed in Austria.
Dejaco D; Steinbichler T; Schartinger VH; Fischer N; Anegg M; Dudas J; Posch A; Widmann G; Riechelmann H
BMJ Open; 2019 Feb; 9(2):e025359. PubMed ID: 30782931
[TBL] [Abstract][Full Text] [Related]
20. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
